Oncocyte Corporation Begins Manufacturing of Transplant Blood Test

Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), is addressing a market of more than one million annual testing opportunities in the United States as it begins manufacturing its transplant blood test.

Oncocyte believes its patented method of assessing graft damage offers distinct benefits over competing and more invasive approaches. Early access for the company’s Research Use Only (RUO) kit is expected to open in late Q4 2023.

Highlights

Oncocyte has begun the manufacturing process for the distributable version of its patented transplant technology.

The assay provides a method of checking for signs of graft damage in transplant recipients, measuring levels of donor derived cell-free DNA in the blood.

The test provides a simple, easy-to-use workflow, on droplet digital PCR, so researchers can perform in-house testing. It can typically be accomplished within the same day, without the necessity of donor genotyping.

About Oncocyte

Oncocyte is a precision diagnostics company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and pipeline test DetermaCNI™ is a blood-based monitoring tool for assessing therapeutic efficacy in cancer patients. VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. For more information, visit www.oncocyte.com or LinkedIn for updates.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Oncocyte Corporation Begins Manufacturing of Transplant Blood Test

Editor Prism MarketView